DELIVERY AND PROLONGATION OF RANIBIZUMAB ACTION IN HYDROGEL DRAINAGE DURING ANTIGLAUCOMA SURGERY

Abstract

Analyzing literature sources, we have not found any studies on the prolongation of the properties of the vascular endothelial growth factor inhibitor (anti-VEGF drugs) in glaucoma surgery. The article presents the results of application of the developed hydrogel as a ranibizumab carrier in glaucoma surgeries. Hydrogel drainage was prepared directly before surgery. For this, a ranibizumab drug solution (0.23 ml) was mixed with a hyaluronic acid dialdehyde solution (0.5 ml), then a chitosan succinate solution(0.5 ml) was added. The hydrogel dosage form was formed during a minute at indoor temperature. The content of the drug in the hydrogel was 0,187-0,200 ml per 1 ml of gel (RF patent of invention №2610368 dt. 10/26/15). Experimental studies were carried out on 12 (12 eyes) healthy rabbits. In vitro and in vivo experiments proved that ranibizumab introduced in 0.1 ml of hydrogel drainage into glaucoma surgery, released gradually during 3 weeks and inhibited the proliferation of connective tissue.